SCHEMBL1482999

SCHEMBL1482999

CCCc1ccc(-c2c(O)c(/C(C)=N\NC(=O)c3ccc(C(=O)OC)cc3)nn2C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
PLK1 P53350 1/20 0.37
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
POLB P06746 3/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
KMT2A Q03164 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
CYP4A11 Q02928 2/20 0.36
GAA P10253 3/20 0.35
MAPK1 P28482 1/20 0.35
MAPT P10636 5/20 0.35
LMNA P02545 2/20 0.35
MITF O75030 1/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP4F2 P78329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1483001 1.00 KDM4E (0.37) KDM4EPLK1ALDH1A1SMN1; SMN2HPGD
SCHEMBL1484322 0.94 MAPT (0.42) ALDH1A1SMN1; SMN2KMT2ACYP4A11MAPT
SCHEMBL1484320 0.94 MAPT (0.42) ALDH1A1SMN1; SMN2KMT2ACYP4A11MAPT
SCHEMBL1484359 0.93 MAPK1 (0.41) KDM4EALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL1484361 0.93 MAPK1 (0.41) KDM4EALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL1483795 0.93 MAPT (0.42) ALDH1A1SMN1; SMN2KMT2ACYP4A11MAPT
SCHEMBL1483797 0.93 MAPT (0.42) ALDH1A1SMN1; SMN2KMT2ACYP4A11MAPT
SCHEMBL1483781 0.90 RAB9A (0.40) KDM4EPLK1ALDH1A1SMN1; SMN2POLB
SCHEMBL1483778 0.90 RAB9A (0.40) KDM4EPLK1ALDH1A1SMN1; SMN2POLB
SCHEMBL12829657 0.90 RAB9A (0.40) KDM4EPLK1ALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636192-B9 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL IND LTD (JP) 2015-07-01 EP disclosed
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2014-02-20 US disclosed
EP-1636192-B1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL IND LTD (JP) 2014-01-15 EP disclosed
US-20130012708-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2013-01-10 US disclosed
US-8318796-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-11-27 US disclosed
US-20110077290-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2011-03-31 US disclosed
US-7576115-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-08-18 US disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077290-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KDM4E 4480/4885PLK1 4010/4885ALDH1A1 3234/4885
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NR2C2, ROR1, NR0B2 KDM4E 4422/4885PLK1 4043/4885ALDH1A1 3160/4885
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KDM4E 4486/4885PLK1 3989/4885ALDH1A1 3206/4885
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KDM4E 4480/4885PLK1 4010/4885ALDH1A1 3234/4885
US-20130012708-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KDM4E 4480/4885PLK1 4010/4885ALDH1A1 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.